Doximity (DOCS)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$26.35-2.77%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Doximity grows revenue about 6% yearly, guided to $670M in fiscal 2027. The company manages CFO transition and announced a share buyback to boost value. Profit margins and cash flow remain stable. The platform's focus on healthcare professionals supports lasting demand.
Growth is slowing with recent earnings misses and guidance cuts. AI spending pressures may hurt margins and revenue growth. CFO changes create uncertainty. The stock trades below peers and faces high risk.
The price is about 25% below our fair value near $32, reflecting cautious views. Analysts expect about 6% revenue growth, which aligns with company guidance. Our fair value is above the Street median, showing some upside if execution improves.
Breaks if: CFO transition causes material financial or operational disruption
Manage the transition of the Chief Financial Officer position effectively.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is a growth play focused on the healthcare sector. DOCS is working to expand its AI-driven platform while managing a recent CFO transition, indicating a commitment to long-term growth despite some challenges.
The current valuation suggests that the market views DOCS as relatively cheap compared to its peers. However, there is a slight expectations gap, indicating that the market is not overly optimistic about future performance.
Recent financial performance has been strong, with revenue growth and an increase in active prescribers. However, the company has a history of earnings misses, which adds some uncertainty to its near-term trajectory.
The long-term thesis hinges on the company's ability to sustain revenue growth through its AI initiatives and navigate the CFO transition effectively. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Revenue growth guidance remains intact, driven by AI-driven platform expansion. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $640M in FY27
Maintain revenue growth with guidance for fiscal year ending March 31, 2027.
Breaks if: Share buyback program is cancelled or materially reduced
Overall, DOCS appears to be on a stable path, but high risks and external pressures could impact its future. Not investment advice.